MannKind Corporation (MNKD) exhibits 92.3% gross margins and 54.5% return on invested capital within Health Care (Biotechnology: Pharmaceutical Preparations), balanced against a 24.6x enterprise multiple and 4.8% implied options volatility.
Sustained 92.3% gross profitability converts into 11.1% operating margin and 54.5% ROIC, outpacing sector cost of capital.
ROIC: 54.5% // GM: 92.3%YoY revenue trajectory of +22.2% paired with 1.22% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +22.2% // FCF YLD: 1.22%Altman Z-Score of 0.20 and Piotroski F-Score of 7/9 indicate low near-term refinancing stress.
ALTMAN Z: 0.20 // F-SCORE: 7/9Trading at 24.0x trailing P/E (— Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 24.0x // EV/EBITDA: 24.6xOptions market prices a ±5.2% implied move with a 0.85 put/call ratio around $3.50 max pain.
IMPL MOVE: ±5.2% // P/C: 0.85Elevated industry capital intensity and customer concentration in Biotechnology: Pharmaceutical Preparations require continuous execution to defend 1.7% net margins.
NET MARGIN: 1.7% // D/E: 0.45x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for MNKD & activate live FRED threshold breach alerts.